Resultados de la búsqueda 131-140 of 6821 for Benfotiamine

1. Hematología - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This is a prospective, pilot, single arm study to evaluate the incidence of IIC in patients with solid malignancies receiving VSL#3 and ICIs.

3. Hematología - Ensayos clínicos - Mayo Clinic

   Rochester, Minn. The purpose of this study is to determine how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma ...

4. Médicos y departamentos

   Alergia al trigo · Liu M, et al. Allergenicity of wheat protein in diet: Mechanisms, modifications and challenges. · Wheat allergy. American College of Allergy, ...

5. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

6. Bispecific antibody therapy - Mayo Clinic

   Discover how this therapy can treat cancers such as lymphoma and other diseases. Learn about risks and clinical trials.

7. Hematología - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

8. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

9. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

10. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...